科研之友
微信
新浪微博
Facebook
分享链接
摘要
Aggregation and accumulation of A(42) play an initiating role in Alzheimer's disease (AD); thus, selective lowering of A(42) by -secretase modulators (GSMs) remains a promising approach to AD therapy. Based on evidence suggesting that steroids may influence A production, we screened 170 steroids at 10 M for effects on A(42) secreted from human APP-overexpressing Chinese hamster ovary cells. Many acidic steroids lowered A(42), whereas many nonacidic steroids actually raised A(42). Studies on the more potent compounds showed that A(42)-lowering steroids were bonafide GSMs and A(42)-raising steroids were inverse GSMs. The most potent steroid GSM identified was 5-cholanic acid (EC50=5.7 M; its endogenous analog lithocholic acid was virtually equipotent), and the most potent inverse GSM identified was 4-androsten-3-one-17-carboxylic acid ethyl ester (EC50=6.25 M). In addition, we found that both estrogen and progesterone are weak inverse GSMs with further complex effects on APP processing. These data suggest that certain endogenous steroids may have the potential to act as GSMs and add to the evidence that cholesterol, cholesterol metabolites, and other steroids may play a role in modulating A production and thus risk for AD. They also indicate that acidic steroids might serve as potential therapeutic leads for drug optimization/development.Jung, J. I., Ladd, T. B., Kukar, T., Price, A. R., Moore, B. D., Koo, E. H., Golde, T. E., Felsenstein, K. M. Steroids as -secretase modulators.
- 出版日期2013-9
